Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Levilain

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Organic Process Research & Development|September 9, 2020
A Structured Approach To Cope with Impurities during Industrial Crystallization DevelopmentStephanie J Urwin, Guillaume Levilain, Ivan Marziano, et al.
Journal of Medicinal Chemistry|June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced CoagulopathyHartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
Journal of Medicinal Chemistry|September 24, 2020
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Hartmut Beck, Tobias Thaler, Daniel Meibom, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Organic Process Research & Development|September 9, 2020
A Structured Approach To Cope with Impurities during Industrial Crystallization DevelopmentStephanie J Urwin, Guillaume Levilain, Ivan Marziano, et al.
Journal of Medicinal Chemistry|June 11, 2025
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced CoagulopathyHartmut Beck, Stefanie Mesch, Stefanie Zimmermann, et al.
Journal of Medicinal Chemistry|September 24, 2020
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Hartmut Beck, Tobias Thaler, Daniel Meibom, et al.
Pageof 1